Oct. 31, 2019: HCV treatment efficacy regardless of injection drug use; chronic pain, marijuana, and prescription opoids; the most urgent HIV training priorities; neuro effects of switching from Atripla to Complera.
An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).
Sep. 5, 2019: An extra decade of "heart age"; stop grouping trans women with MSM; women often have anal cancer precursor lesions; hep C treatment success doesn't equal more risk behavior.
Aug. 29, 2019: Viral load blips, low-level viremia, and eventual virologic failure; pinpointing non-adherence as a cause of HIV treatment failure; HIV care costs vary widely throughout U.S.; Kaposi sarcoma incidence in the modern HIV treatment era.
Aug. 8, 2019: Casual sex partners increase among U.S. MSM; why some MSM undervalue PrEP; proteinuria prevalence and fracture risk; cannabis, cocaine, and inflammation in people living with HIV.
"Providing HCV treatment alone while neglecting to concurrently address the social determinants of health will do little to improve the health outcomes of the majority of individuals with chronic HCV," the study authors wrote.
Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.
'Drug Users Are People Too': Addressing Opioid Addiction, Chemsex, Alcoholism, and Smoking Among People Living With HIV
A CROI 2019 symposium demonstrated the need for continued research and programs that address substance use and its impact on people living with HIV.
The global increase in sexually transmitted infections was a major focus of the CROI 2019 meeting in Seattle, Washington.
Alternate PrEP guideline recommendations; partner notification and onward HIV transmission; shifting causes of death among HIV/HCV-coinfected people; correlates of lower adherence among people on methadone maintenance.